Abstract
CD8 T cells play an important role in autoimmune diabetes development, and therefore removing these cells may protect against disease. To test this, we designed a novel method using engineered cells (InsCD3-zeta) to target insulin-specific CD8 T cells. Insulin-reactive target cells were cultured with InsCD3-zeta CD8 T cells and cytotoxicity was assessed. Activated, but not naïve, InsCD3-zeta CD8 T cells readily killed insulin-reactive target CD8 T cells. This approach to immunotarget relevant pathogenic CD8 T cells may be a therapeutic option to delay or prevent type 1 diabetes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
CD3 Complex / genetics
-
CD8-Positive T-Lymphocytes / drug effects*
-
CD8-Positive T-Lymphocytes / metabolism
-
Cell Death / drug effects
-
Cytotoxicity, Immunologic / genetics
-
Cytotoxins / pharmacology
-
Cytotoxins / therapeutic use*
-
Diabetes Mellitus, Type 1 / genetics
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / prevention & control*
-
Disease Models, Animal*
-
Female
-
Insulin / metabolism*
-
Lymphocyte Activation / drug effects
-
Mice
-
Mice, Inbred NOD
-
Mice, Transgenic
Substances
-
CD3 Complex
-
CD3 antigen, zeta chain
-
Cytotoxins
-
Insulin